Live
- Tata Group to create 5 lakh manufacturing jobs over next half decade: N. Chandrasekaran
- Hansika’s charm remains undeniable
- Housing Sales Decline 4% in 2024, but Sales Value Rises 16% in India’s Top Cities: ANAROCK
- VHP to launch campaign from Jan 5 to free temples from govt control
- Israeli far-right minister visits flashpoint Jerusalem holy site, sparking criticism
- Keralites gulp down liquor worth Rs 152 crore over Christmas period
- Nani exudes style & intensity in ‘HIT 3’ new poster
- Journalist-writer Dr Rentala Jayadeva comes with a book ‘Mana Cinema.. First Reel’
- Harish Rao Criticizes Government’s Delayed Response to Sandhya Theatre Incident
- Apple Watch Ultra 3 to Include BP Monitoring and Satellite Texting by 2025
Plasma therapy not beneficial: ICMR Study
Plasma therapy not beneficial: ICMR Study
Use of convalescent plasma therapy in Coronavirus-infected patients does not help in reducing mortality or progression to severe COVID-19, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found
New Delhi: Use of convalescent plasma therapy in Coronavirus-infected patients does not help in reducing mortality or progression to severe COVID-19, a multi-centric study funded by the Indian Council of Medical Research (ICMR) has found.
The 'open-label parallel-arm phase II multicentre randomized controlled trial' (PLACID Trial) was conducted across 39 public and private hospitals across India between April 22 to July 14 to investigate the effectiveness of convalescent plasma (CP) for the treatment of COVID-19, it said.
The convalescent plasma (CP) therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those antibodies into an active coronavirus patient to help kickstart the immune system to fight the infection.
A total of 464 participants (moderately ill COVID-19 patients admitted to hospitals) were enrolled for the study, which has not yet been peer-reviewed and has appeared on medRxiv, a preprint server.
The National Task Force for COVID-19, a committee formed by the ICMR to respond to the pandemic, has reviewed and approved this study, it said.
